ClinicalTrials.gg
RecruitingNCT07522931RETRO-PELVISUpdated Nov 12, 2026

Systematic Anatomical Description of the Female Pelvic Retroperitoneum in Cadavers

An observational study in Pelvic Anatomy, Retroperitoneum and Cadaveric Study, sponsored by Hospital Universitari de Bellvitge. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hospital Universitari de Bellvitge · Observational

How we know

Updated Nov 12, 2026Study documents postedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years and older
Sex
Female
01

Study summary

This observational descriptive cadaveric study aims to describe the main anatomical relationships of the female pelvic retroperitoneum using standardized anatomical dissection. Adult female cadavers obtained from an institutional body donation program will undergo pelvic retroperitoneal dissection. Ten predefined anatomical relationships involving the ureter, pelvic vessels and nerves will be evaluated using a standardized anatomical checklist. Anatomical variability will be described for each item. Standardized photographs will also be obtained to develop an anatomical atlas for educational purposes.

Read the detailed description

This is an observational, descriptive cadaveric study designed to characterize the main anatomical relationships of the female pelvic retroperitoneum with direct application to gynecologic surgery.

The study will be conducted using adult female cadavers obtained from an institutional body donation program. Approximately 20 cadavers will be included, depending on availability, providing a total of 40 hemipelves. Each hemipelvis will be considered an independent unit of analysis.

Standardized anatomical dissections of the pelvic retroperitoneum will be performed following a predefined protocol. The main anatomical structures relevant to gynecologic surgery will be identified, including the pelvic ureter, iliac vessels and their branches, obturator nerve, and other predefined anatomical landmarks.

Each hemipelvis will be evaluated using a standardized 10-item anatomical checklist. For every item, the reference anatomical pattern will be classified as present ("Yes"), absent ("No"), or not evaluable ("Not evaluable"). Anatomical variability will be calculated as the proportion of anatomical variants among all evaluable hemipelves for each item.

Standardized photographic documentation will be obtained throughout the dissections. Anatomical variants will be qualitatively described and illustrated whenever possible.

Statistical analysis will be descriptive. Categorical variables will be presented as absolute frequencies and percentages. Anatomical variability will be reported for each checklist item, excluding non-evaluable observations from the denominator.

This study does not involve living human participants, clinical interventions, or identifiable personal data. All procedures will be conducted in accordance with institutional and ethical standards governing the use of donated human bodies for research and education.

The expected outcome is a systematic description of the principal anatomical relationships of the female pelvic retroperitoneum and their anatomical variability, together with the development of a photographic anatomical atlas to support surgical training and gynecologic education.

02

Conditions studied

  • Pelvic Anatomy
  • Retroperitoneum
  • Cadaveric Study
  • Surgical Anatomy

Keywords

  • Pelvic anatomy
  • retroperitoneum
  • female pelvis
  • Dissection
  • cadaver
  • cadaveric model
  • surgical anatomy
  • Gynecologic surgery
  • Morphometric analysis
  • Anatomical variability
  • Nerve-sparing surgery
  • Pelvic vessels
  • Ureter anatomy
  • Hypogastric plexus
  • Pelvic lymphatic anatomy
03

In context

Lead sponsor

Hospital Universitari de Bellvitge is the lead sponsor of 120 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult female cadavers from the institutional body donation program.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female cadavers from an institutional body donation program
  • Age ≥ 18 years at time of death
  • Adequate preservation of pelvic and abdominal retroperitoneal structures
  • Anatomical integrity allowing identification of the pelvic ureter, iliac vessels and their main branches, obturator nerve, and other structures included in the anatomical checklist.
  • Availability of both hemipelves for comparative analysis
  • Authorization for research use according to institutional body donation regulations

Exclusion criteria

Exclusion Criteria:

  • Male cadavers
  • Prior major pelvic or abdominal surgery significantly altering retroperitoneal anatomy (e.g., hysterectomy, lymphadenectomy, vascular surgery)
  • History of pelvic or abdominal radiotherapy
  • Advanced pelvic or abdominal with retroperitoneal involvement
  • Severe trauma affecting pelvic or abdominal anatomy
  • Poor preservation or significant tissue degradation
  • Absence of one or both hemipelves
  • Advanced pregnancy at time of death
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cadaveric Specimens

    Adult female cadavers obtained from an institutional body donation program. Specimens will undergo standardized pelvic retroperitoneal dissection, completion of a predefined 10-item anatomical checklist, and photographic documentation.

    Other: Anatomical Dissection

Interventions

  • OtherAnatomical Dissection

    Standardized pelvic retroperitoneal dissection with completion of a 10-item anatomical checklist, observations and photographic documentation.

06

What researchers measure

Primary outcomes

  1. Frequency of anatomical variation

    Percentage of anatomical variation for each of the ten predefined anatomical relationships evaluated using a standardized anatomical checklist.

    Time frame: Baseline

Secondary outcomes

  1. Development of an anatomical atlas

    Standardized photographic documentation of anatomical structures and variants for educational purposes.

    Time frame: Baseline

07

Study locations

1 of 2 sites recruiting
  • Universitat de Barcelona - Department of Anatomy and Human Embryology
    Barcelona, Barcelona 08007, Spain
    Recruiting
  • Universitat de Barcelona - Department of Anatomy and Human Embryology
    Barcelona, 08028, Spain
    Not yet recruiting
    • Josep Maria de Anta Vinyals Chief of Department Anatomy and Embriology, Anatomist · Contactjanta@ub.edu
08

References and documents

Publications

  • Cibula D, Abu-Rustum NR. Pelvic lymphadenectomy in cervical cancer--surgical anatomy and proposal for a new classification system. Gynecol Oncol. 2010 Jan;116(1):33-7. doi: 10.1016/j.ygyno.2009.09.003. Epub 2009 Oct 17. PubMed 19837449 ↗
  • Sanna B, Henry BM, Vikse J, Skinningsrud B, Pekala JR, Walocha JA, Cirocchi R, Tomaszewski KA. The prevalence and morphology of the corona mortis (Crown of death): A meta-analysis with implications in abdominal wall and pelvic surgery. Injury. 2018 Feb;49(2):302-308. doi: 10.1016/j.injury.2017.12.007. Epub 2017 Dec 9. PubMed 29241998 ↗
  • Sienkiewicz-Zawilinska J, Zawilinski J, Kaythampilla LN, Jankiel M, Urbaniak J, Bereza T, Kowalski W, Loukas M, Walocha J. Autonomic nervous system of the pelvis - general overview. Folia Med Cracov. 2018;58(2):21-44. doi: 10.24425/fmc.2018.124656. PubMed 30467432 ↗
  • Ripperda CM, Jackson LA, Phelan JN, Carrick KS, Corton MM. Anatomic relationships of the pelvic autonomic nervous system in female cadavers: clinical applications to pelvic surgery. Am J Obstet Gynecol. 2017 Apr;216(4):388.e1-388.e7. doi: 10.1016/j.ajog.2016.12.002. Epub 2016 Dec 9. PubMed 27956200 ↗
  • Kostov S, Slavchev S, Dzhenkov D, Mitev D, Yordanov A. Avascular Spaces of the Female Pelvis-Clinical Applications in Obstetrics and Gynecology. J Clin Med. 2020 May 13;9(5):1460. doi: 10.3390/jcm9051460. PubMed 32414119 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this study does not involve living participants or identifiable individual-level clinical data. The study is based on anonymized cadaveric specimens and generates aggregate anatomical and morphometric data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Sep 2027, 10 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Apr 2026 → Nov 2026, primary completion Sep 2026 → Sep 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 13, 2026
StartEst.
Nov 14, 2026was Apr 2026
Primary completionEst.
Sep 28, 2027was Sep 2026
CompletionEst.
Nov 30, 2027was Nov 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 14, 2026→Nov 14, 2026
Nov 12, 2026
Primary completion
Sep 28, 2026→Sep 28, 2027
Nov 12, 2026
Study completion
Nov 30, 2026→Nov 30, 2027
Nov 12, 2026
Documents
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Documents Study protocol ↗ posted
    Start date Apr 14, 2026→Nov 14, 2026
    Primary completion Sep 28, 2026→Sep 28, 2027
    Study completion Nov 30, 2026→Nov 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07522931
Responsible party
Jorge García Fernández (Gynaecologyst, Hospital Universitari de Bellvitge) — Principal investigator
First posted
Apr 13, 2026
Start date
Nov 14, 2026 (estimated)
Primary completion
Sep 28, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Jorge Garcia Fernandez Principal Investigator, Gynecologist
Contact
jorgarciafernan@gmail.com
+34622595644
Jorge García Fernández, Gynecologist
principal investigator · Hospital Universitari de Bellvitge

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion